BioCentury | Aug 23, 2019
Distillery Therapeutics

KRAS inhibitor combinations for improved therapeutic efficacy

DISEASE CATEGORY: Cancer INDICATION: Lung cancer, pancreatic cancer UCSF’s Kevan Shokat and colleagues have identified two sets of genes for which inhibition could improve the efficacy of KRAS G12C inhibitors. Through a CRISPR-based screen in...
BioCentury | Jun 8, 2017
Clinical News

Cyclin D3-CDK6 levels predict tumor response to CDK4/6 inhibitors

...an article published online in Nature on Wednesday, scientists reported that high levels of tumor cyclin D3-cyclin-dependent...
...levels of cyclin D3 and CDK6. In contrast, non-regressing tumors all had low pre-xenograft levels of cyclin D3...
...and CDK6. In contrast, non-regressing tumors all had low pre-xenograft levels of cyclin D3 and CDK6. Cyclin D3...
BioCentury | Sep 15, 2016
Distillery Therapeutics

Therapeutics: Angiogenin ribonuclease RNase A family 5 (ANG)

Hematology INDICATION: Bone marrow transplant (BMT); poisoning Cell culture and mouse studies suggest ANG could help improve outcomes in BMT patients and treat radiation damage. In cultures of primary mouse hematopoietic stem cells (HSCs), recombinant...
BioCentury | Aug 15, 2016
Emerging Company Profile

Restraining translation

Bantam Pharmaceutical LLC is developing small molecule eukaryotic translation initiation factor 4E inhibitors that selectively inhibit translation of several tumor-promoting genes and disrupt cancer cell metabolism. It hopes to show the mechanism of its lead...
BioCentury | Dec 14, 2015
Product Development

Following CoMMpass

Amidst a flood of promising data for hot targets, indications and technologies at this year's American Society of Hematology meeting, one collection of presentations stands out not only for the wide-reaching implications of their data,...
BioCentury | Sep 24, 2015
Distillery Techniques

Techniques: SNPs on oligonucleotide/oligosaccharide-binding fold containing 1 (OBFC1) and other loci as risk markers of cutaneous malignant melanoma

Biomarkers OBFC1 cyclin D1 CCND1 BCL1 oligonucleotide/oligosaccharide-binding fold containing 1 (OBFC1) QIMR Berghofer Medical Research Institute University of Leeds BC Staff...
BioCentury | Jun 18, 2015
Distillery Techniques

Techniques: Crystal structure of myeloid leukemia cell differentiation protein (MCL1)

Drug platforms TECHNOLOGY: Crystal structures Crystallographic studies on an MCL1 fusion protein could aid the structure-based design of MCL1-specific inhibitors. A fusion of maltose binding protein and MCL1 containing three mutations to enhance its crystal...
BioCentury | Apr 30, 2015
Distillery Therapeutics

Therapeutics: Myeloid leukemia cell differentiation protein (MCL1); B cell lymphoma 2 (BCL-2; BCL2); Bcl-XL

Cancer INDICATION: Cancer In vitro studies identified a tricyclic indole-based, selective inhibitor of MCL1 that could help treat cancer. Fragment-based drug design, chemical synthesis and in vitro testing of tricyclic 2-indole carboxylic acid analogs identified...
BioCentury | Aug 29, 2013
Distillery Therapeutics

Indication: Cancer

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Breast cancer; prostate cancer Androgen receptor; cyclin D1 (CCND1; BCL1) In vitro and mouse studies identified acetamide analog small molecules that...
BioCentury | Dec 10, 2012
Clinical News

PD-0332991: Additional Phase II data

Combined data from 66 postmenopausal women with estrogen receptor-positive, HER2-negative advanced breast cancer in part 1 and 99 postmenopausal women whose tumors revealed cyclin D1 ( CCND1 ; BCL1 ) amplification and p16 loss in part 2...
Items per page:
1 - 10 of 37